Renal osteodystrophy, the term used to describe the skeletal complications of end-stage renal disease, is a multifactorial disorder of bone remodeling. The actions of some of the factors involved are well defined, and successful strategies have been designed to prevent them. For example, the identification of secondary hyperparathyroidism and 1Î±,25-dihydroxycholecalciferol (1Î±,25-dihydroxyvitamin D3) deficiency as major contributors to renal osteodystrophy has led to the development of treatment regimens that can maintain normal serum calcium and phosphate concentrations, reduce parathyroid hormone secretion, and correct a deficiency of 1Î±,25-dihydroxycholecalciferol. These improvements in treatment have resulted in decreases in the frequency and.Â .Â .
|Number of pages||9|
|Journal||New England Journal of Medicine|
|State||Published - Jul 20 1995|